JP7653513B2 - 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 - Google Patents

非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 Download PDF

Info

Publication number
JP7653513B2
JP7653513B2 JP2023517830A JP2023517830A JP7653513B2 JP 7653513 B2 JP7653513 B2 JP 7653513B2 JP 2023517830 A JP2023517830 A JP 2023517830A JP 2023517830 A JP2023517830 A JP 2023517830A JP 7653513 B2 JP7653513 B2 JP 7653513B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023517830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530037A (ja
JP2023530037A5 (https=
Inventor
ワイダンツ，ジョン
アップチャーチ－アンジュ，キャサリン
Original Assignee
べーリンガー インゲルハイム インターナショナル ゲーエムベーハー
ベーリンガー インゲルハイム インターナショナル ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by べーリンガー インゲルハイム インターナショナル ゲーエムベーハー, ベーリンガー インゲルハイム インターナショナル ゲーエムベーハー filed Critical べーリンガー インゲルハイム インターナショナル ゲーエムベーハー
Publication of JP2023530037A publication Critical patent/JP2023530037A/ja
Publication of JP2023530037A5 publication Critical patent/JP2023530037A5/ja
Application granted granted Critical
Publication of JP7653513B2 publication Critical patent/JP7653513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2023517830A 2020-06-01 2021-06-01 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 Active JP7653513B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032886P 2020-06-01 2020-06-01
US63/032,886 2020-06-01
US17/199,258 2021-03-11
US17/199,258 US11976120B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
PCT/US2021/035291 WO2021247608A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (3)

Publication Number Publication Date
JP2023530037A JP2023530037A (ja) 2023-07-12
JP2023530037A5 JP2023530037A5 (https=) 2023-08-03
JP7653513B2 true JP7653513B2 (ja) 2025-03-28

Family

ID=78829884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517830A Active JP7653513B2 (ja) 2020-06-01 2021-06-01 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法

Country Status (18)

Country Link
US (2) US11976120B2 (https=)
EP (1) EP4157884A4 (https=)
JP (1) JP7653513B2 (https=)
KR (1) KR20230019469A (https=)
CN (1) CN116157157A (https=)
AU (1) AU2021283201A1 (https=)
BR (1) BR112022023933A2 (https=)
CA (1) CA3174102A1 (https=)
CL (1) CL2022003299A1 (https=)
CO (1) CO2022018430A2 (https=)
CR (1) CR20220650A (https=)
DO (1) DOP2022000265A (https=)
EC (1) ECSP22097203A (https=)
IL (1) IL298061A (https=)
JO (1) JOP20220308A1 (https=)
MX (1) MX2022015129A (https=)
PE (1) PE20230374A1 (https=)
WO (1) WO2021247608A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210253713A1 (en) * 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20240415884A1 (en) * 2022-02-01 2024-12-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Molecules that bind to cd276 polypeptides
CN120077068A (zh) * 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165307A1 (en) 2018-02-23 2019-08-29 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
WO2020023548A1 (en) 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
JP2020506962A (ja) 2017-01-24 2020-03-05 アベクサ バイオロジクス，インク． 癌における非古典的ｈｌａ−ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
EP3475706B1 (en) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506962A (ja) 2017-01-24 2020-03-05 アベクサ バイオロジクス，インク． 癌における非古典的ｈｌａ−ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
WO2019165307A1 (en) 2018-02-23 2019-08-29 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
WO2020023548A1 (en) 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Immunology，2002年，Vol.32, No.4，pp.936-944

Also Published As

Publication number Publication date
DOP2022000265A (es) 2023-01-15
CN116157157A (zh) 2023-05-23
AU2021283201A1 (en) 2023-02-02
KR20230019469A (ko) 2023-02-08
JP2023530037A (ja) 2023-07-12
CA3174102A1 (en) 2021-12-09
US20220033504A1 (en) 2022-02-03
PE20230374A1 (es) 2023-03-06
IL298061A (en) 2023-01-01
EP4157884A1 (en) 2023-04-05
ECSP22097203A (es) 2023-02-28
MX2022015129A (es) 2023-03-24
JOP20220308A1 (ar) 2022-11-15
CL2022003299A1 (es) 2023-07-07
CO2022018430A2 (es) 2022-12-30
EP4157884A4 (en) 2024-06-19
WO2021247608A1 (en) 2021-12-09
BR112022023933A2 (pt) 2023-04-11
US20230303701A1 (en) 2023-09-28
CR20220650A (es) 2023-05-25
US11976120B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
JP7653513B2 (ja) 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法
JP7545438B2 (ja) Ｖｉｓｔａ抗原結合性分子
JP7650351B2 (ja) 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法
US11873346B2 (en) VISTA antigen-binding molecules
US10981997B1 (en) Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CA2863818A1 (en) Cancer treatment and monitoring methods using ox40 agonists
JP2024512567A (ja) Ｔ細胞リンパ腫の診断および治療方法
CN107850596A (zh) 用于检测组织浸润nk细胞的方法
CA3147164A1 (en) Antibody combinations for treatment of cancer in specific patients
CN112118868A (zh) 预防和治疗髓样来源的抑制细胞相关疾病的用途
CN110343180A (zh) 抗ctla-4抗体及其应用
CN120303295A (zh) 使用vista抗原结合分子治疗和预防癌症
JP2024535053A (ja) Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
WO2022268857A2 (en) Vhh-based nkp30 binders
TW202235440A (zh) 靶向包含非典型hla-i及新生抗原之複合物的抗體及其使用方法
HK40128218A (zh) 用於治疗特定患者的癌症的抗体组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250317

R150 Certificate of patent or registration of utility model

Ref document number: 7653513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150